Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CTH | P32929 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 3/20 | 0.33 |
| ▸ | MMP9 | P14780 | 3/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11741240 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2CTHMEN1KMT2APOLB | |
| SCHEMBL12424103 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2CTHMEN1KMT2APOLB | |
| SCHEMBL9548201 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2CTHMEN1KMT2APOLB | |
| SCHEMBL9548205 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2CTHMEN1KMT2APOLB | |
| SCHEMBL85699 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1KMT2APOLBGAA | |
| SCHEMBL13451733 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1KMT2APOLBGAA | |
| SCHEMBL12611248 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2MEN1KMT2APOLBLMNA | |
| SCHEMBL11735520 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2MEN1KMT2APOLBLMNA | |
| SCHEMBL7519164 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1KMT2APOLBGAA | |
| SCHEMBL9548185 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2CTHMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339649-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2020-10-29 | — | — | US | claimed |
| EP-3645031-A1 | PEPTIDE ANALOGS | Adepthera LLC (US) | 2020-05-06 | — | — | EP | claimed |
| WO-2019005623-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC (US) | 2019-01-03 | — | — | WO | claimed |
| EP-0603206-A4 | NEUROTENSIN METHOD FOR INHIBITING VASCULAR LEAKAGE. | UNIV CALIFORNIA (US) | 1995-04-12 | — | — | EP | claimed |
| US-5374621-A | Administering modified peptide before or after tissue injury | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-12-20 | — | — | US | claimed |
| EP-0603206-A1 | NEUROTENSIN METHOD FOR INHIBITING VASCULAR LEAKAGE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-06-29 | — | — | EP | claimed |
| WO-1993006130-A1 | NEUROTENSIN METHOD FOR INHIBITING VASCULAR LEAKAGE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-04-01 | — | — | WO | claimed |
| US-11390657-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2022-07-19 | — | — | US | disclosed |
| US-20200339649-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2020-10-29 | — | — | US | disclosed |
| EP-3645031-A1 | PEPTIDE ANALOGS | Adepthera LLC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190153059-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2019-05-23 | — | — | US | disclosed |
| WO-2019005623-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20070148164-A1 | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto | BIOGEN IDEC MA INC. (US) | 2007-06-28 | — | — | US | disclosed |
| EP-0603206-A4 | NEUROTENSIN METHOD FOR INHIBITING VASCULAR LEAKAGE. | UNIV CALIFORNIA (US) | 1995-04-12 | — | — | EP | disclosed |
| US-5374621-A | Administering modified peptide before or after tissue injury | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-12-20 | — | — | US | disclosed |
| EP-0603206-A1 | NEUROTENSIN METHOD FOR INHIBITING VASCULAR LEAKAGE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993006130-A1 | NEUROTENSIN METHOD FOR INHIBITING VASCULAR LEAKAGE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339649-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | SMN1; SMN2 4342/4885CTH 2580/4885MEN1 872/4885 |
| US-20190153059-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | SMN1; SMN2 4342/4885CTH 2580/4885MEN1 872/4885 |
| US-11390657-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | SMN1; SMN2 4521/4885CTH 2808/4885MEN1 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.